Behandling med nukleosidanaloger bør stoppes hvis der opstår symptomatisk hyperlactatæmi og metabolisk acidose/ lactacidose, fremadskridende hepatomegali eller hurtigt stigende aminotransferase - niveauer.
Treatment with nucleoside analogues should be discontinued if there is symptomatic hyperlactatemia and metabolic/ lactic acidosis, progressive hepatomegaly, or rapidly elevating aminotransferase levels.